ChemDiv sees great potential in this acquisition by adding value to ChemDiv’s Discovery outSource services offered to pharmaceutical and biotech companies worldwide.
Nikolay Savchuk, president and CEO of ChemDiv, said: “This acquisition is synergistic to the continued development of our Chemical Diversity Research Institute subsidiary, and our other discovery services holdings such as Drugs Technology, which provides good laboratory practice/good manufacturing practice formulation and CMC services.
“We believe Prudentas will help us bring unique levels of clinical development productivity to pharma and biotech partners through risk mitigation, cost- and time savings. This acquisition further strengthens and expands our global presence specifically in the Eastern European and Eurasian markets and responds to growing customer demand for comprehensive R&D outsourcing.”